阿托伐他汀对慢性肾衰并贫血患者微炎性反应的影响  

Influence of atorvastatin on inflammatory mediators in patients with chronic renal failure combined anemia

作　　者：张燕燕[1] 张晓东[1] 李瑛[1] 李辉[1] 

机构地区：[1]武警后勤学院附属医院肾病科,天津市300162

出　　处：《中国基层医药》2013年第13期1926-1927,共2页Chinese Journal of Primary Medicine and Pharmacy

基　　金：基金项目：天津市自然科学基金资助项目（09JcYBJc09900）

摘　　要：目的分析阿托伐他汀在慢性肾衰并贫血患者维持性血液透析期间对微炎性因子的影响。方法慢性肾衰并贫血患者按随机数字表法分为两组，对照组60例进行维持性血液透析，观察组60例患者在透析期间联合应用阿托伐他汀治疗，比较两组患者治疗3个月后炎性因子及贫血状况的变化。结果治疗3个月，观察组患者TC、TG、LDL-C以及HDL．C获得显著改善（P〈0．05），分别是（3．41±1．24）mmol／L、（1．35±0．58）mmol／L、（1．63±0．83）mmol／L、（2．61±0．69）mmol／L，且上述指标与同期对照组比较差异有统计学意义（P〈0．05）。观察组患者hs—CRP、IL-6、TNF-α均较治疗前显著降低（P〈0．05），改善明显优于对照组。观察组应用促红细胞生成素剂量显著低于对照组（P〈0．05）。结论阿托伐他汀通过改善高脂血症，降低患者体内的微炎性状态，提高其对贫血治疗的敏感性。Objeetive To analyze the influence of atorvastatin on inflammatory mediators in patients with chronic renal failure combined anemia. Methods 120 patients with chronic renal failure combined anemia were se- lected and randomly divided into two groups. The patients in control group underwent regular maintenance hemodialysis（MHD） ,while the patients in observation group received MHD combined with atorvastatin. Comparison was made between two groups in the aspect of inflammatory mediators and clinical effect of anemia after 3 months. Results After three months treatment, TC,TG, LDL-C, BNP, hs-CRP, IL-6, TNF-α, were significantly decreased after treatment in observation group （P 〈 0.05）, which was （ 3.41±1.24 ） mmol/L, （ 1.35±0.58 ） retool/L, （ 1.63±0.83 ） mmol/L, （2. 61±0.69）mmol/L,respectively and they were significantly improved than those in control group after treatment （P 〈 0.05 ）. The prescribed erythropoietin-stimulating agent dose in observation group was significantly lower than that in the control group（P 〈 0.05）. Conclusion Atorvastatin could lead to lower micro-inflammation and reduce the dosage of erythropoietin-stimulating agent.

关 键 词：肾功能衰竭 慢性 阿托伐他汀 贫血 C反应蛋白质 白细胞介素6 肿瘤坏死因子α 肾透析 

分 类 号：R692.5[医药卫生—泌尿科学]